

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/780,917
				Filing Date	02/19/2004
				First Named Inventor	Lesley Murray
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1035
Sheet	1	of	1		

[illegible]

Examiner Signature	/Shirley Gembah/	Date Considered	06/01/2006
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/780,917
		Filing Date	02/19/2004
		First Named Inventor	Lesley Murray
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-1035
Sheet	1	of	4

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
SG	A1	6,573,293	B2	TANG et al.	06-03-2003	
SG	A2	6,642,232	B2	MATTSON et al.	11-04-2003	
SG	A3	6,653,308	B2	GUAN et al.	11-25-2003	
SG	A4	2004/0018528	A1	MORIMOTO et al.	01-29-2004	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
SG	A5	WO	00/08202	A2	SUGEN, INC.	02-17-2000		
SG	A6	WO	01/60814	A2	SUGEN, INC.	08-23-2001		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
SG	A7	BRANDI et al., "Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms," <u>Proc. Natl. Acad. Sci. USA</u> , March 1995, pp. 2954-2958, Vol. 92	
SG	A8	CLOHISY et al., "Review of Cellular Mechanisms of Tumor Osteolysis," <u>Clinical Orthopaedics and Related Research</u> , 2000, pp. 104-114, No. 373, Lippincott Williams & Wilkins, Inc.	
SG	A9	COLEMAN et al., "Osteoclast inhibition for the treatment of bone metastases," <u>Cancer Treatment Reviews</u> , January 1993, pp. 79-103, Vol. 19, No. 1, Academic Press Limited	

Examiner Signature	/Shirley Gembeh/	Date Considered	06/01/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/780,917
		Filing Date	02/19/2004
		First Named Inventor	Lesley Murray
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-1035
Sheet	2	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SG	A10	DAVIES et al., "The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor," <u>The Journal of Cell Biology</u> , October 1989, pp. 1817-1826, Vol. 109, No. 4, Part 1, The Rockefeller University Press	
	A11	DEMERS et al., "Biochemical Markers and Skeletal Metastases," <u>Cancer Supplement</u> , June 15, 2000, pp. 2919-2926, Vol. 88, No. 12, John Wiley & Sons, Inc.	
	A12	FISHER et al., "Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein," <u>Endocrinology</u> , 1993, pp. 1411-1413, Vol. 132, No. 3, The Endocrine Society, USA	
	A13	FLICK et al., "Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody," <u>Oncogene</u> , May 29, 1997, pp. 2553-2561, Vol. 14, No. 21, Stockton Press	
	A14	FRIEDMAN et al., "Thyroidal calcitonin: Inhibitor of Bone Resorption in Tissue Culture," <u>Science</u> , December 10, 1965, pp. 1465-1467, Vol. 150	
	A15	HALL et al., "Taxol Inhibits Osteoclastic Bone Resorption," <u>Calcified Tissue International</u> , December 1995, pp. 463-465, Vol. 57, No. 6, Springer-Verlag New York Inc.	
	A16	HENTUNEN et al., "Inhibition of Bone Resorption by a Monoclonal Antibody That Reacts with a 150 kD Membrane Protein in Chicken Osteoclasts," <u>Journal of Bone and Mineral Research</u> , October 1991, pp. 1091-1097, Vol. 6, No. 10, Mary Ann Liebert, Inc. Publishers	
	A17	HUNT et al., "Cellular mechanisms of bone resorption in breast carcinoma," <u>British Journal of Cancer</u> , 2001, pp. 78-84, Vol. 85, No. 1, Cancer Research Campaign	
	A18	JILKA et al., "Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6," <u>Science</u> , July 3, 1992, pp. 88-91, Vol. 257	
	A19	KACINSKI et al., "FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas <i>in vivo</i> and <i>in vitro</i> ," <u>Oncogene</u> , June 1991, pp. 941-952, Vol. 6, No. 6, Macmillan Press Ltd.	
	A20	KACINSKI, "CSF-1 and Its Receptor in Ovarian, Endometrial and Breast Cancer," <u>Annals of Medicine</u> , February 1995, pp. 79-85, Vol. 27, No. 1	
SG	A21	KACINSKI, "CSF-1 and Its Receptor in Breast Carcinomas and Neoplasms of the Female Reproductive Tract," <u>Molecular Reproduction and Development</u> , January 1997, pp. 71-74, Vol. 46, No. 1, Wiley-Liss	

Examiner Signature	/Shirley Gembeh/	Date Considered	06/01/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/780,917
		Filing Date	02/19/2004
		First Named Inventor	Lesley Murray
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	034536-1035
(use as many sheets as necessary)			
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SG	A22	MAHER et al., "Prognostic Significance of Colony-stimulating Factor Receptor Expression in Ipsilateral Breast Cancer Recurrence," <u>Clinical Cancer Research</u> , August 1998, pp. 1851-1856, Vol. 4, No. 8, American Association of Cancer Research	
	A23	MANCINO et al., "Breast Cancer Increases Osteoclastogenesis by Secreting M-CSF and Upregulating RANKL in Stromal Cells," <u>Journal of Surgical Research</u> , September 2001, pp. 18-24, Vol. 100, No. 1, Academic Press	
	A24	MUNDY, "Regulation of Bone Formation by Bone Morphogenetic Proteins and Other Growth Factors," <u>Clinical Orthopaedics and Related Research</u> , 1996, pp. 24-28, No. 323, Lippincott-Raven Publishers	
	A25	MUNDY, "Cytokines and Growth Factors in the Regulation of Bone Remodeling," <u>Journal of Bone and Mineral Research</u> , December 1993, pp. S505-S510, Vol. 8, Supplement 2, Mary Ann Liebert, Inc., Publishers	
	A26	O'NEILL et al., "Effect of Retinoic Acid on the Resorptive Activity of Chick Osteoclasts <i>in Vitro</i> ," <u>Bone</u> , 1992, pp. 23-27, Vol. 13, No. 1, Pergamon Press plc, USA	
	A27	PEDERSON et al., "Identification of Breast Cancer Cell Line-derived Paracrine Factors That Stimulate Osteoclast Activity," <u>Cancer Research</u> , November 15, 1999, pp. 5849-5855, Vol. 59	
	A28	QUINN et al., "Human Tumour-Associated Macrophages Differentiate Into Osteoclastic Bone-Resorbing Cells," <u>Journal of Pathology</u> , January 1998, pp. 31-36, Vol. 184, No. 1, John Wiley & Sons, Ltd.	
	A29	ROBINS et al., "Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation," <u>Clinical Chemistry</u> , 1996, pp. 1621-1626, Vol. 42, No. 10	
	A30	SCHMIDT et al., "Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry," <u>Clinical & Experimental Metastasis</u> , 1999, pp. 537-544, Vol. 17, No. 6, Kluwer Academic Publishers, Netherlands	
	A31	TAKAHASHI et al., "Downregulation of Calcitonin Receptor mRNA Expression by Calcitonin during Human Osteoclast-like Cell Differentiation," <u>J. Clin. Invest.</u> , January 1995, pp. 167-171, Vol. 95, No. 1, The Rockefeller University Press	
	A32	TAMURA et al., "The Relationship between Urinary Pyridinoline, Deoxypyridinoline and Bone Metastasis in a Rat Breast Cancer Model," <u>Breast Cancer</u> , January 1999, pp. 23-28, Vol. 6, No. 1	
SG	A33	TANAKA et al., "Macrophage Colony-stimulating Factor is Indispensable for both Proliferation and Differentiation of Osteoclast Progenitors," <u>J. Clin. Invest.</u> , January 1993, pp. 257-263, Vol 91, No. 1, The Rockefeller University Press	

Examiner Signature	/Shirley Gembeh/	Date Considered	06/01/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/780,917
		Filing Date	02/19/2004
		First Named Inventor	Lesley Murray
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
(use as many sheets as necessary)		Attorney Docket Number	034536-1035
Sheet	4	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
SG	A34	TANG et al., "M-CSF (Monocyte Colony Stimulating Factor) and M-CSF Receptor Expression by Breast Tumour Cells: M-CSF Mediated Recruitment of Tumour Infiltrating Monocytes?" <u>Journal of Cellular Biochemistry</u> , December 1992, pp. 350-356, Vol. 50, No. 4, Wiley-Liss, Inc.	
	A35	TOY et al., "The Activated Macrophage Colony-Stimulating Factor (CSF-1) Receptor as a Predictor of Poor Outcome in Advanced Epithelial Ovarian Carcinoma," <u>Gynecologic Oncology</u> , 2001, pp. 194-200, Vol. 80, Academic Press	
	A36	WEBBER et al., "Correlation of an Osteoclast Antigen and Ruffled Border on Giant Cells Formed in Response to Resorbable Substrates," <u>Journal of Bone and Mineral Research</u> , 1990, pp. 401-410, Vol. 5, No. 4, Mary Ann Liebert, Inc., Publishers	
	A37	YASUDA et al., "Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL," <u>Proc. Natl. Acad. Sci. USA</u> , March 1998, pp. 3597-3602, Vol. 95, The National Academy of Sciences	
	A38	YEE et al., "The Constitutive Production of Colony Stimulating Factor 1 by Invasive Human Breast Cancer Cells," <u>Anticancer Research</u> , November-December 2000, pp. 4379-4384, Vol. 20, No. 6B	
SG	A39	YONEDA et al., "Suramin Suppresses Hypercalcemia and Osteoclastic Bone Resorption in Nude Mice Bearing a Human Squamous Cancer," <u>Cancer Research</u> , May 1, 1995, pp. 1989-1993, Vol. 55, No. 9	

Examiner Signature	/Shirley Gembeh/	Date Considered	06/01/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.